专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2751280B1 METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY 有权
标题翻译：方法预测患有一抗血管生成疗法有关的高血压的风险
公开(公告)号：EP2751280B1
公开(公告)日：2016-06-29
申请号：EP12750601.2
申请日：2012-08-28
申请人： F.Hoffmann-La Roche AG , VIB VZW , Life Sciences Research Partners VZW
发明人： DE HAAS, Sanne, Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K39/3955 , A61K45/06 , C12Q2600/106 , C12Q2600/156

2. 发明授权

EP2462242B1 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 有权
标题翻译：响应中的血管生成抑制剂
公开(公告)号：EP2462242B1
公开(公告)日：2015-04-01
申请号：EP10744513.2
申请日：2010-08-03
申请人： F.Hoffmann-La Roche AG , VIB VZW , Life Sciences Research Partners VZW
发明人： FOERNZLER, Dorothee , DELMAR, Paul , SCHERER, Stefan , LAMBRECHTS, Diether , CARMELIET, Peter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156

3. 发明公开

EP2783015A1 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 审中-公开
标题翻译：对血管生成抑制剂的反应
公开(公告)号：EP2783015A1
公开(公告)日：2014-10-01
申请号：EP12788199.3
申请日：2012-11-19
申请人： F.Hoffmann-La Roche AG , VIB VZW , Life Sciences Research Partners VZW
发明人： CARMELIET, Peter , DE HAAS, Sanne Lysbet , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determing the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.
摘要翻译：本发明涉及通过确定VEGFR-1基因的基因型来确定患者是否更适合通过血管生成抑制剂（例如贝伐单抗）的疗法治疗的方法。本发明进一步涉及包含血管发生抑制剂（例如贝伐单抗）的药物组合物，用于基于VEGFR-1基因的基因型治疗患有癌症的患者。本发明进一步涉及基于VEGFR-1基因的基因型，通过添加血管生成抑制剂如贝伐珠单抗来改善患有癌症的患者的化疗的治疗效果的方法。

4. 发明公开

EP2751281A1 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 审中-公开
标题翻译： ANSPRECHEMPFINDLICHKEIT AUF ANGIOGENESEHEMMER
公开(公告)号：EP2751281A1
公开(公告)日：2014-07-09
申请号：EP12750781.2
申请日：2012-08-28
申请人： F.Hoffmann-La Roche AG , VIB VZW , Life Sciences Research Partners VZW
发明人： DE HAAS, Sanne Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , C12Q1/6827 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determing the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene.
摘要翻译：本发明涉及通过确定VEGF启动子基因和/或VEGFR2基因的基因型来确定患者是否通过用血管生成抑制剂如贝伐单抗的治疗更适当地治疗的方法。本发明还涉及包含血管生成抑制剂如贝伐珠单抗的基于VEGF启动子基因和/或VEGFR2基因的基因型治疗患有癌症的患者的药物组合物。本发明还涉及基于VEGF启动子基因和/或VEGFR2基因的基因型，通过添加血管发生抑制剂如贝伐单抗来改善患有癌症的患者的化疗的治疗效果的方法。

5. 发明公开

EP2751280A1 METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY 有权
标题翻译：方法预测患有一抗血管生成疗法有关的高血压的风险
公开(公告)号：EP2751280A1
公开(公告)日：2014-07-09
申请号：EP12750601.2
申请日：2012-08-28
申请人： F.Hoffmann-La Roche AG , VIB VZW , Life Sciences Research Partners VZW
发明人： DE HAAS, Sanne, Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K39/3955 , A61K45/06 , C12Q2600/106 , C12Q2600/156
摘要： The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.

6. 发明公开

EP2462242A2 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 有权
标题翻译：响应中的血管生成抑制剂
公开(公告)号：EP2462242A2
公开(公告)日：2012-06-13
申请号：EP10744513.2
申请日：2010-08-03
申请人： F.Hoffmann-La Roche AG , VIB VZW , Life Sciences Research Partners VZW
发明人： FOERNZLER, Dorothee , DELMAR, Paul , SCHERER, Stefan , LAMBRECHTS, Diether , CARMELIET, Peter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene.

7. 发明申请

WO2013076029A1 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 审中-公开
标题翻译：对血液生成抑制剂的反应
公开(公告)号：WO2013076029A1
公开(公告)日：2013-05-30
申请号：PCT/EP2012/072953
申请日：2012-11-19
申请人： F. HOFFMANN-LA ROCHE AG , VIB VZW , LIFE SCIENCES RESEARCH PARTNERS VZW , CARMELIET, Peter , DE HAAS, Sanne Lysbet , LAMBRECHTS, Diether , SCHERER, Stefan
发明人： CARMELIET, Peter , DE HAAS, Sanne Lysbet , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determing the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.
摘要翻译：本发明涉及通过确定VEGFR-1基因的基因型来确定患者是否通过用血管发生抑制剂如贝伐珠单抗的治疗更适当地治疗的方法。本发明还涉及包含血管生成抑制剂如贝伐珠单抗的基于VEGFR-1基因的基因型治疗患有癌症的患者的药物组合物。本发明还涉及基于VEGFR-1基因的基因型，通过添加血管发生抑制剂如贝伐珠单抗来改善患有癌症的患者的化疗的治疗效果的方法。

8. 发明申请

WO2013030167A1 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 审中-公开
标题翻译：对血液生成抑制剂的反应
公开(公告)号：WO2013030167A1
公开(公告)日：2013-03-07
申请号：PCT/EP2012/066630
申请日：2012-08-28
申请人： F. HOFFMANN-LA ROCHE AG , VIB vzw , Life Sciences Research Partners vzw , DE HAAS, Sanne Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
发明人： DE HAAS, Sanne Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , C12Q1/6827 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determing the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene.
摘要翻译：本发明涉及通过确定VEGF启动子基因和/或VEGFR2基因的基因型来确定患者是否通过用血管发生抑制剂如贝伐珠单抗的治疗更适当地治疗的方法。本发明进一步涉及包含血管生成抑制剂如贝伐珠单抗的基于VEGF启动子基因和/或VEGFR2基因的基因型治疗患有癌症的患者的药物组合物。本发明还涉及基于VEGF启动子基因和/或VEGFR2基因的基因型，通过添加血管生成抑制剂（例如贝伐珠单抗）来改善患有癌症的患者的化疗的治疗效果的方法。

9. 发明申请

WO2013030168A1 METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY 审中-公开
标题翻译：预防与抗血栓形成治疗相关的高血压风险的方法
公开(公告)号：WO2013030168A1
公开(公告)日：2013-03-07
申请号：PCT/EP2012/066632
申请日：2012-08-28
申请人： F. HOFFMANN-LA ROCHE AG , VIB VZW , LIFE SCIENCES RESEARCH PARTNERS VZW , DE HAAS, Sanne, Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
发明人： DE HAAS, Sanne, Lysbet , DELMAR, Paul , LAMBRECHTS, Diether , SCHERER, Stefan
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K39/3955 , A61K45/06 , C12Q2600/106 , C12Q2600/156
摘要： The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
摘要翻译：本发明涉及通过确定KDR基因和/或EGF基因的基因型来预测患者与抗血管生成治疗相关的高血压易感性（例如贝伐珠单抗）的方法。本发明还涉及包含血管生成抑制剂如贝伐珠单抗的基于KDR基因和/或EGF的基因型治疗患有癌症的患者的药物组合物。本发明还涉及通过测定KDR基因和/或EGF基因的基因型，降低与患有癌症的患者中的抗血管生成治疗如贝伐珠单抗相关的高血压风险的方法。

10. 发明公开

EP3153592A1 RESPONSIVENESS TO ANGIOGENESIS INHIBITORS 审中-公开
标题翻译： ANSPRECHEMPFINDLICHKEIT AUF ANGIOGENESEHEMMER
公开(公告)号：EP3153592A1
公开(公告)日：2017-04-12
申请号：EP16194527.4
申请日：2010-08-03
申请人： F. Hoffmann-La Roche AG , VIB vzw , Life Sciences Research Partners VZW
发明人： FOERNZLER, Dorothee , DELMAR, Paul , SCHERER, Stefan , LAMBRECHTS, Diether , CARMELIET, Peter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene.
摘要翻译：本发明涉及通过用血管发生抑制剂如贝伐单抗进行治疗来改善患有恶性疾病或涉及生理和病理性血管发生的疾病的患者的总体存活的方法，通过确定一种或多种变异等位基因的存在，血管内皮生长因子受体1（VEGFR-1）基因。本发明还提供了通过用血管发生抑制剂如贝伐珠单抗治疗来改善患有恶性疾病或涉及生理和病理性血管发生的疾病的患者的无进展生存的方法，通过确定一种或多种变异等位基因的存在的VEGFR-1基因。本发明还提供了通过确定VEGFR-1基因的一个或多个变体等位基因的存在来评估患者对血管生成抑制剂的反应性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式